No Survival Benefit When Adding Everolimus to Trastuzumab and Paclitaxel in Advanced HER2-Positive BC

Article Figures & Data

Figures

  • Figure 1.

    Progression-Free Survival in the BOLERO-1 Entire Study Population

    One-sided P value is obtained from the log-rank test stratified by prior use of trastuzumab (yes/no) and visceral metastasis (yes/no) from Interactive Web Response System.

    Reproduced with permission from SA Hurvitz, MD.